[Evaluation of nephrotoxicity of combined administration of cephaloridine and gentamicin based on the studies of urinary lysosomal enzyme and alkaline phosphatase activities].
D000328:Adult; D000469:Alkaline Phosphatase / Q000652:urine; D002509:Cephaloridine / Q000008:administration & dosage / Q000633:toxicity*; D004359:Drug Therapy, Combination; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000633:toxicity*; D005966:Glucuronidase / Q000652:urine; D006596:Hexosaminidases / Q000652:urine; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D001616:beta-Galactosidase / Q000652:urine
D005839:Gentamicins; D000469:Alkaline Phosphatase; D006596:Hexosaminidases; D001616:beta-Galactosidase; D005966:Glucuronidase; D002509:Cephaloridine
Ocena nefrotoksyczności łacznego podawania cefalorydyny i gentamycyny na podstawie badania aktywności enzymów lizosomalnych i fosfatazy zasadowej w moczu.